CLVS - クロビス・オンコロジ― (Clovis Oncology Inc.) クロビス・オンコロジ―

 CLVSのチャート


 CLVSの企業情報

symbol CLVS
会社名 Clovis Oncology Inc (クロビス・オンコロジ―)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 クロービス・オンコロジー(Clovis Oncology Inc.)は米国、ヨーロッパ及び他の国際市場における抗癌剤の取得・開発・商品化に従事するバイオ医薬品会社である。同社の製品候補にはロシリチニブ、ルブラカ(ルカパリブ)及びルシチニブを含む。ルカパリブは損傷デオキシリボ核酸乳癌(DNA)の修復関連ヒト遺伝子の乳がん(BRCA)突然変異患者の治療向け単剤療法として承認されたPARP1、PARP2及びPARP3の経口小分子ポリアデノシン二リン酸(ADP)・リボースポリメラーゼ(PARP)阻害剤である。ルシチニブは、血管内皮増殖因子受容体(VEGFR)1-3、血小板由来増殖因子受容体(PDGFR)αとβ及び線維芽細胞増殖因子受容体(FGFR)1-3のチロシンキナーゼ活性の経口阻害剤である。ロシリチニブは表皮成長因子受容体(EGFR)の経口突然変異選択的阻害剤である。   クロビス・オンコロジ―は米国のバイオ医薬品会社。抗がん剤の買収、開発、商業化を手掛ける。非小細胞肺がん治療用に経口の選択的・非可逆的EGFR阻害剤CO-186を、また、卵巣がんおよびすい臓がん治療用にポリ(ADP-リボ―ス)ポリメラ―ゼ阻害剤ルカパリブの臨床開発を実施している。   Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, with additional office locations in the U.S. and Europe.
本社所在地 5500 Flatiron Parkway Suite 100 Boulder CO 80301 USA
代表者氏名 M. James E. Barrett M.ジェームスE.バレット
代表者役職名 Independent Chairman of the Board
電話番号 +1 303-625-5000
設立年月日 39904
市場名 NASDAQ National Market System
ipoyear 2011年
従業員数 360人
url www.clovisoncology.com
nasdaq_url https://www.nasdaq.com/symbol/clvs
adr_tso
EBITDA EBITDA(百万ドル) -268.68600
終値(lastsale) 30.34
時価総額(marketcap) 1597388590.94
時価総額 時価総額(百万ドル) 1531.05
売上高 売上高(百万ドル) 76.12600
企業価値(EV) 企業価値(EV)(百万ドル) 1423.143
当期純利益 当期純利益(百万ドル) -129.23100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Clovis Oncology Inc revenues increased 95% to $42.3M. Net loss decreased 24% to $178.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Legal settlement loss decrease of 93% to $8M (expense) Other income increase from $948K to $2.9M (income).

 CLVSのテクニカル分析


 CLVSのニュース

   Can These Former Biotech Growth Stocks Regain Their Form?  2021/09/29 14:00:00 The Motley Fool
Acadia Pharmaceuticals and Clovis Oncology may be turnaround stories in the making.
   Clovis Oncology (CLVS) Investor Presentation - Slideshow  2021/09/24 23:05:22 Seeking Alpha
   Boulder-based Clovis pays off notes, raises more than $40M  2021/09/21 00:05:47 Daily Camera
In an effort to clean up its balance sheet, cancer-drug manufacturer Clovis Oncology Inc. (NYSE: CLVS) has paid off $64.4 million in maturing convertible senior notes due in 2021 and raised more than $40 million in new financing through at-the-market offerings.
   Astonishing stocks: Clovis Oncology, Inc. (NASDAQ:CLVS 0.65%), Bridgeline Digital, Inc. (NASDAQ:BLIN 0.00%)  2021/09/17 23:51:31 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Astonishing stocks: Clovis Oncology, Inc. (NASDAQ:CLVS 0.65%), Bridgeline Digital, Inc. (NASDAQ:BLIN 0.00%) appeared first on Stocks Equity .
   Why Clovis Oncology Shares Got a Bump This Week  2021/08/27 15:37:13 The Motley Fool
Shares of the biotech that focuses on oncology drugs climbed more than 12% during the week.
   Why Clovis Oncology Shares Got a Bump This Week  2021/08/27 15:37:13 The Motley Fool
Shares of the biotech that focuses on oncology drugs climbed more than 12% during the week.
   Clovis Oncology Announces Renewal of At-The-Market Equity Offering Program  2021/08/16 20:21:00 Business Wire
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (SEC)
   Nothing seems to bother NYSE:AVA, NASDAQ:CLVS, NYSE:K, NASDAQ:BHF  2021/08/08 12:58:00 Stock Market Daily
Quarterly, annual earnings. See the latest EPS estimates vs Actual and surprise it caused. Stock Market Daily has their analysis The post Nothing seems to bother NYSE:AVA, NASDAQ:CLVS, NYSE:K, NASDAQ:BHF appeared first on .
   Clovis reports $66.4M loss for Q2 2021  2021/08/05 01:12:31 Colorado Daily
Cancer-drug manufacturer Clovis Oncology Inc. posted a net loss of $66.4 million, or $0.61 per share, in its second quarter earnings that were reported Wednesday.
   Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q2 2021 Results - Earnings Call Transcript  2021/08/05 00:34:03 Seeking Alpha
   Senseonics and Clovis Oncology gain ahead of inclusion in Russell Indexes  2021/06/25 18:07:36 Seeking Alpha
   A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE)  2021/06/25 16:00:00 Clinical Trials Gov
Condition : Solid Tumor Interventions : Drug: 68Ga-FAP-2286; Drug: 177Lu-FAP-2286 Sponsor : Clovis Oncology, Inc. Recruiting
   Pancreatic Cancer Diagnostic Devices Market to Witness Revolutionary Growth by 2026 | Amgen, Clovis Oncology, Myriad Genetics  2021/06/25 07:00:00 iCrowdNewswire
The latest study released on the Global Pancreatic Cancer Diagnostic Devices Market by AMA Research evaluates market size, trend, and forecast to 2026. The Pancreatic Cancer Diagnostic Devices market study []
   Clovis starts enrollment of phase 1/2 trial for candidate to treat tumors  2021/06/23 11:39:39 Seeking Alpha
   Stock Gigantic Turns: Clovis Oncology, Inc. (NASDAQ:CLVS), Two Harbors Investment Corp. (NYSE:TWO)  2021/06/22 20:57:44 Stock Equity
Clovis Oncology, Inc. (NASDAQ:CLVS) with the stream of -2.01% also noticed, India Two Harbors Investment Corp. (NYSE:TWO) encountered a rapid change of -0.12% in the last hour of Tuesdays trading The post Stock Gigantic Turns: Clovis Oncology, Inc. (NASDAQ:CLVS), Two Harbors Investment Corp. (NYSE:TWO) appeared first on Stocks Equity .

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 クロビス・オンコロジ― CLVS Clovis Oncology Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)